

EXPLANATORY NOTE

This Amendment No. 1 to Current Report on Form 8-K/A (this “Form 8-K/A”) is an amendment to the Current Report on Form 8-K of ImmunoGen, Inc. (also referred to as “we” or “our”), filed with the Securities and Exchange Commission (SEC) on June 27, 2019 (the “Original Form 8-K”). We disclosed in the Original Form 8-K that our intent was to seek to sub-lease a majority of our office space at 830 Winter St. in Waltham and dispose of excess equipment subsequent to a restructuring of our business. At the time the Original Form 8-K was filed, we could not estimate the loss we expect to incur in connection with the disposition of that space and equipment. In accordance with SEC rules, we are filing this Form 8-K/A now that we have determined an estimate of the loss.

ITEM 2.05 – COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES

In accordance with current accounting standards, we have determined that after consideration of the balances of our right-to-use asset and leasehold improvements, the market lease rates for comparable properties, the amount of time we expect it will take to sub-lease the space and other factors, we will not incur a loss on the estimated sub-lease arrangement. After estimating fair values of our equipment to be disposed of, an impairment loss related to this equipment in the amount of \$2.5 million was recorded as part of the restructuring charge. This estimated charge will be included in our results for the period ended June 30, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmunoGen, Inc.

(Registrant)

Date: August 5, 2019

/s/ David G. Foster

David G. Foster

Vice President and Chief Accounting Officer
